PRESS RELEASES

Denifanstat Showed Statistically Significant Improvements Across Key Disease Markers in FASCINATE-2 Study After 26 Weeks of Treatment  Highlights to be

Additional Preclinical Data on Denifanstat Published in Scientific Reports  San Mateo, California, October 31, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical

San Mateo, California, October 24, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,

San Mateo, California, September 13, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced

San Mateo, California, August 4, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced

San Mateo, California, June 8, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered,

Company Adopts Denifanstat as Non-Proprietary Name for TVB-2640 San Mateo, California, May 4, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company

San Mateo, California, November 12, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will give an oral presentation on consolidated results from the Phase 2 FASCINATE-1 trial of Sagimet’s lead clinical candidate TVB-2640 in patients in the U.S. and China with nonalcoholic steatohepatitis (NASH) on November 14 at The Liver Meeting 2021. The presentation is entitled “Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China.”